Core Viewpoint - The stock price of CSPC Pharmaceutical Group has shown strong performance, currently at 10 HKD, reflecting a 0.71% increase, with technical indicators suggesting continued upward momentum [1] Technical Analysis - The stock price has broken through all major moving averages, with the 10-day moving average at 9.29 HKD and the 30-day moving average at 8.5 HKD forming a perfect bullish arrangement [1] - The RSI indicator is at 74, indicating an overbought condition, while the William's indicator also shows overbought status; however, the MACD maintains a strong buy signal with the fast and slow lines diverging upwards, reflecting robust upward momentum [1] Key Price Levels - A significant support level is established at 9.1 HKD, coinciding with the 30-day moving average and a psychological barrier; a stronger support level is at 8.5 HKD [2] - The initial resistance level is at 11.1 HKD, and a breakthrough could lead to a challenge of the 12 HKD mark; the Bollinger Bands indicate a clear expansion, with the stock price closely following the upper band, suggesting potential for increased short-term volatility [2] Derivative Market Performance - During the rally from July 28 to July 30, the Societe Generale call warrant (17287) achieved an impressive 52% increase, while the JPMorgan call warrant (18044) saw a 46% rise, showcasing the explosive potential of leveraged products during CSPC's single-day surge of 10.99% [4] Selected Warrant Products Analysis - The Morgan Stanley call warrant (17483) offers a 4x actual leverage with an exercise price of 10.99 HKD, making it suitable for short-term participation in breakout scenarios; the Bank of China call warrant (17351) provides a more conservative 3.3x leverage for cautious investors [7] - UBS call warrant (17646) has an exercise price of 10.95 HKD with a leverage of 2.83x, while another Bank of China call warrant (17640) at the same exercise price offers a leverage of 2.8x with a premium of 28.93% [7] Operational Strategy Recommendations - In the context of the stock being in an overbought zone, aggressive investors may consider holding call warrants to capitalize on the potential breakout above the 11.1 HKD resistance level; conservative investors are advised to wait for the RSI to retreat to neutral territory before making further investments [10] - Close attention to policy changes in the pharmaceutical industry is recommended, as these can serve as significant catalysts for short-term price fluctuations [10]